18.6.2025 23:41:14 CEST | Thor Medical ASA | Major shareholding notifications

Oslo, Norway, 18 June 2025: Reference is made to the stock exchange
announcements by Thor Medical ASA (the "Company") on 18 June 2025 regarding the
completion of a private placement of new shares to be issued by the Company (the
"Private Placement") and a retail offering through PrimaryBid (the "PrimaryBid
Offering").

Scatec Innovation AS has agreed to lend existing and unencumbered shares in the
Company, already being traded on Euronext Oslo Børs, to Arctic Securities AS and
DNB Carnegie, a part of DNB Bank ASA (the "Managers") for the Private Placement
and the PrimaryBid Offering. Borrowed shares will be used for settlement towards
investors having been allocated shares in the Private Placement and the
PrimaryBid Offering and redelivered to Scatec Innovation AS upon registration of
the share capital increase pertaining to the Private Placement and the
PrimaryBid Offering.

Prior to the completion of the Private Placement, Scatec Innovation AS held
78,419,309 shares in the Company, representing approx. 24.94% of the issued
share capital and votes. Scatec Innovation AS has lent a total of 31,577,399
existing shares which will be delivered to the investors in the Private
Placement and the PrimaryBid Offering other than Scatec Innovation AS. During
the term of the loan, and prior to the redelivery, Scatec Innovation AS'
shareholding in the Company will be reduced to 46,841,910, equivalent to approx.
14.90% of the issued share capital and votes. Consequently, Scatec Innovation AS
has fallen below the 20 and 15% thresholds pursuant to section 4-2 (1) and (3)
of the Norwegian Securities Trading Act.

In addition, Scatec Innovation AS has controlling interest in Scatec Invest IV
AS, which holds 1,281,338 shares in the Company. Scatec Innovation AS'
aggregated shareholding is thus 48,123,248 after the share lending, equivalent
to approx. 15,31% of the issued share capital and votes in the Company.

The board of directors of the Company has resolved to issue 30,000,000 offer
shares in the Private Placement and 4,577,399 offer shares in the PrimaryBid
Offering pursuant to the authorisation granted by the Company's annual general
meeting held on 24 April 2025, that will be subscribed by the Managers, and,
once issued, delivered to Scatec Innovation AS as redelivery of shares borrowed
in relation to settlement of the Private Placement and the PrimaryBid Offering,
as well as delivery of 3,000,000 shares allocated to Scatec Innovation AS in the
Private Placement.

Scatec Innovation AS is a close associate of chairman John Andersen. Primary
insider notification pursuant to the market abuse regulation article 19 is
attached.

This announcement is published in accordance with section 4-2 of the Norwegian
Securities Trading Act and is subject to disclosure requirements pursuant to the
EU Market Abuse Regulation article 19 (3) and the Norwegian Securities Trading
Act section 5-12.

Contacts

Brede Ellingsæter, CFO & COO, Thor Medical ASA, +47 472 38 440, 
brede.ellingseter@thormedical.com

ABOUT THOR MEDICAL ASA

Thor Medical is an emerging supplier of radionuclides, primarily alpha particle
emitters, from naturally occurring thorium. Its proprietary production process
requires no irradiation or use of nuclear reactors, and provides reliable,
environmentally friendly, cost-efficient supply of alpha-emitters for the
radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and
listed on the Oslo Stock Exchange under the ticker symbol 'TRMED'.

To learn more, visit www.thormedical.no - http://www.thormedical.no 

 

ATTACHMENTS

Download announcement as PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18570366/6227/Download%20announce
ment%20as%20PDF.pdf

20250618 - Primary insider notifications Scatec Innovation AS.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18570366/6226/20250618%20-%20Prim
ary%20insider%20notifications%20Scatec%20Innovation%20AS.pdf